<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700658</url>
  </required_header>
  <id_info>
    <org_study_id>TV46046-WH-10147</org_study_id>
    <nct_id>NCT03700658</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous Administration of TV-46046</brief_title>
  <official_title>A Randomized Cross-over Study to Evaluate Local Tolerability Following Subcutaneous Administration of TV-46046</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the local tolerability associated with the&#xD;
      subcutaneous administration of TV-46046, and inform next steps of the TV-46046 development&#xD;
      program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">October 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The study will be partially blinded due to differences in appearance and volume of the treatments. Designated unblinded study staff will conduct randomization procedures. The staff preparing and administering injections will also be unblinded to treatment sequence but will be trained to shield the syringe prior to and at the time of injection from view of the subject and study staff assessing ISRs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Injection Site Reaction excluding injection site pain</measure>
    <time_frame>Days 0 (immediately after and 1 hour after the injection), 1, 3, 7 and 14, at Months 3 and 6, and at additional visits, if indicated</time_frame>
    <description>Assessed by self-reports and direct observation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Injection Site Pain</measure>
    <time_frame>Day 0 (immediately after and 1 hour after the injection).</time_frame>
    <description>Assessed by Numerical Rating Scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's perception of pain</measure>
    <time_frame>Day 0 (1 hour after the last injection)</time_frame>
    <description>Assessed by an overall ranking of the 4 study injections from least [1] to most [4] painful</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs</measure>
    <time_frame>Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Concomitant Medications</measure>
    <time_frame>Months 1, 2, 3, 4, 5, and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulse respiration rate</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in temperature</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>Day 0 &amp; Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One of 24 sequences</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 1</intervention_name>
    <description>120 mg/0.3 mL</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 2</intervention_name>
    <description>60 mg/0.3 mL of 1:1 saline-diluted TV-46046</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate injectable suspension</intervention_name>
    <description>104 mg/0.65 mL (injectable suspension)</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
    <other_name>Depo-subQ 104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 Placebo</intervention_name>
    <description>0.3 mL</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_label>TV-46046 Placebo</arm_group_label>
    <arm_group_label>medroxyprogesterone acetate injectable suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  has a low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, in&#xD;
             menopause and/or post-menopausal, abstinent, in monogamous relationship with&#xD;
             vasectomized partner, using nonhormonal intrauterine device (IUD) or consistent use of&#xD;
             condoms)&#xD;
&#xD;
          -  is not pregnant and does not have desire to become pregnant in the subsequent 18&#xD;
             months&#xD;
&#xD;
          -  had a normal mammogram within the last year, if 40 years or older&#xD;
&#xD;
          -  has no skin disorders or skin allergies&#xD;
&#xD;
               -  Additional criteria apply, please contact the investigator for more information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has hypertension&#xD;
&#xD;
          -  has ischemic heart disease or a history of ischemic heart disease&#xD;
&#xD;
          -  has a history of stroke&#xD;
&#xD;
          -  has a history of thromboembolic event (s)&#xD;
&#xD;
          -  has systemic lupus erythematosus&#xD;
&#xD;
          -  has rheumatoid arthritis and is undergoing immunosuppressive therapy&#xD;
&#xD;
          -  has migraine with aura&#xD;
&#xD;
          -  has unexplained vaginal bleeding&#xD;
&#xD;
          -  has diabetes&#xD;
&#xD;
          -  has a strong family history of breast&#xD;
&#xD;
          -  has cervical cancer or a history of cervical cancer&#xD;
&#xD;
          -  has severe cirrhosis (decompensated) or liver tumors&#xD;
&#xD;
          -  has known significant renal disease&#xD;
&#xD;
          -  has a history of diagnosed clinical depression or bipolar disorder, with or without&#xD;
             suicidal ideation, and/or history of suicide attempt&#xD;
&#xD;
          -  is currently using hormonal contraception&#xD;
&#xD;
          -  had an injection of DMPA (Depo-Provera CI or Depo-subQ 104) in the past 12 months; or&#xD;
             combined injectable in the last 3 months&#xD;
&#xD;
          -  is chronically using pain medication&#xD;
&#xD;
          -  has a plan to move to another location in the next 18 months&#xD;
&#xD;
               -  Additional criteria apply, please contact the investigator for more information&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceuticals USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 1</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>September 29, 2021</submitted>
    <returned>October 27, 2021</returned>
    <submitted>November 18, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

